Topical Crisaborole in Patients With Alopecia Areata

    Not Recruiting
  • End date
    Dec 1, 2022
  • participants needed
  • sponsor
    Tufts Medical Center
Updated on 5 March 2022
treatment regimen
areata alopecia


The aim of this study is to determine whether topical crisaborole improves hair growth in alopecia areata.


Each individual will be enrolled in the study for 24 weeks. Following a 28 days screening period, eligible subjects will be randomized in a 1:1 ratio to receive either crisaborole 2% ointment or matching placebo for 12 weeks. The primary endpoint is assessed at week 12. At the week 12 visit, all subjects will enter the open label treatment period where they will all receive crisaborole 2% ointment for an additional 12 weeks, with the last study visit taking place on week 24.

Condition Hair Loss, Male Pattern Baldness, areata alopecia, Alopecia Areata, Alopecia
Treatment Crisaborole Topical Ointment, Placebo Topical Ointment
Clinical Study IdentifierNCT04299503
SponsorTufts Medical Center
Last Modified on5 March 2022

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note